Market Trends of Spain Diabetes Drugs and Devices Industry
The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
Continuous blood glucose monitoring (CGM) and multiple daily injections (MDI) have been shown to reduce mild and severe hypoglycemia in patients with type 1 diabetes who are prone to this side effect. People with type 1 diabetes who are at high risk of hypoglycemia can use self-contained continuous blood glucose monitoring, even in dire living conditions imposed by the stringent lockdowns imposed by the COVID-19 pandemic crisis. It may regulate blood sugar levels. Glucose metrics improved slightly during the lockdown period, particularly glucose tolerance-related ones, leading to relief measures.
People with type 1 diabetes (T1D) need to maintain a healthy lifestyle depending on their personality traits, social interactions, socioeconomic status, and living environment factors. The use of continuous glucose monitoring (CGM) with multiple daily injections (MDI) has been shown to reduce non-severe and severe hypoglycemia in type 1 diabetic patients who are prone to this side effect. Patients with type 1 diabetes, at high risk of hypoglycemia, control their blood glucose levels thanks to self-contained continuous blood glucose monitoring, even under harsh living conditions imposed by strict lockdowns due to the COVID-19 pandemic crisis. Small improvements in blood glucose measurement markers, especially those related to glucose tolerance, were associated with the lockdown period. Spanish hospitals have ordered CGM machines to limit staff contact with most COVID-19 diabetic patients. Decisions taken by national bodies such as the Italian Ministry of Health and Spain's Spanish Medical and Health Agency were very limited in scope. These organizations typically have the power to withdraw or reject products but rarely use them for new devices. Spain has the second highest diabetes prevalence in Europe; Spain is also among the top 10 countries in spending on diabetes-related healthcare, with a total of USD 15.5 billion.
Rising diabetes prevalence
In Spain, the number of people with type 1 diabetes is increasing, recording an annual growth rate of more than 3% during the forecast period. Up to 13.8% of adults in Spain have diabetes, and about 6% are believed to have undiagnosed diabetes. A similar prevalence has been identified in the Valencia region of Spain, with a population of 5 million. In this area, general practitioners monitor most diabetic patients and work closely with endocrinologists to treat more complex cases. Many papers point out that people with diabetes are more likely to develop severe COVID-19 infections, have worse outcomes, and have higher mortality rates. The SED expects the death rate to rise further, as the non-diabetic population has a mortality risk of between 0.9% and 3%. Spanish citizens with diabetes are estimated to have a mortality risk of around 7.3%. In Spain, 30.3% of diabetic patients have never been diagnosed. If not properly recognized and treated, diabetes can lead to serious and sometimes fatal consequences such as heart attack, stroke, kidney failure, blindness, and lower limb amputation. They impair the quality of life and increase medical costs.
According to the Spanish Diabetes Association (SED), therapeutic education about diabetes has evolved from a necessity to a priority and an urgency. With the relentless rise in cases and important advances in disease control and treatment, educational efforts with essential equity measures have so far been required to facilitate access to these new resources for all people with diabetes. More is required. SED also recognizes important advances made in the management of diabetes, particularly through technological advances. For example, it approved funding for a flush system for her type 2 diabetic patients on bolus basal insulin therapy.
Suppose diabetes is not diagnosed or adequately treated. In that case, people with diabetes risk serious and life-threatening complications such as heart attack, stroke, kidney failure, blindness and lower limb amputation. This leads to a lower quality of life and higher healthcare costs, resulting in a greater need for access to healthcare. Evidence suggests that diabetes can be successfully managed, especially if detected early. Multicomponent interventions, including glycemic, blood pressure and lipid control, can reduce a wide range of micro- and macrovascular complications and early mortality associated with diabetes.
